KAG-308 , CAS No.1215192-68-9

CAS: 1215192-68-9 Cat. No.: K650159 Formula: C₂₄H₃₀F₂N₄O₃ Molecular Weight: 460.52 PubChem CID: 67108613

Synonyms

HY-128686 | (2Z,3aR,4R,5R,6aS)-3,3-Difluorohexahydro-4-[(1E,3R,4R)-3-hydroxy-4-(3-methylphenyl)-1-penten-1-yl]-2-[4-(2H-tetrazol-5-yl)butylidene]-2H-cyclopenta[b]furan-5-ol | 1215192-68-9 | SCHEMBL1651164 | 4-[(Z)-(1S,5R,6R,7R)-6-[(1E,3R,4R)-3-Hydroxy-4-(

Storage

Store at -20°C,Argon charged

Shipped In

Ice chest + Ice pads

Overview

KAG-308 is a potent selective and orally active agonist of EP4 receptor (a prostaglandin E2 receptor subtype), suppresses colitis and promotes histological mucosal healing, potently inhibits TNF-α production. KAG-308 shows a K i and an EC 50 of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over EP1, EP2, EP3 and IP receptor

In Vitro

KAG-308 is a potent selective and orally active agonist of EP4 receptor, suppresses colitis and promots histological mucosal healing. KAG-308 shows a K i and EC 50 values of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over human EP1 (K i , 1410 nM; EC 50 , 1000 nM), EP2 (K i , 1540 nM; EC 50 , 1000 nM), EP3 (K i , 32.4 nM; EC 50 , 160 nM) and IP receptor (K i , 52.9 nM; EC 50 , >10000 nM). KAG-308 also exhibits potent agonist activity for human and mouse EP4 with an EC 50 of 0.15 nM and 1.0 nM, respectively in the dual luciferase reporter assay. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid

IC50& Target:EC50: 17 nM (Human EP4 receptor), 160 nM (Human EP3 receptor), 1000 nM (Human EP2 receptor), 1000 nM (Human EP2 receptor), Ki: 2.57 nM (Human EP4 receptor), 32.4 nM (Human EP3 receptor), 52.9 nM (Human IP receptor), 1410 nM (Human EP1 receptor), 1540 nM (Human EP2 receptor)

Specifications

Synonyms

HY-128686 | (2Z,3aR,4R,5R,6aS)-3,3-Difluorohexahydro-4-[(1E,3R,4R)-3-hydroxy-4-(3-methylphenyl)-1-penten-1-yl]-2-[4-(2H-tetrazol-5-yl)butylidene]-2H-cyclopenta[b]furan-5-ol | 1215192-68-9 | SCHEMBL1651164 | 4-[(Z)-(1S,5R,6R,7R)-6-[(1E,3R,4R)-3-Hydroxy-4-(

Biochemical and Physiological Mechanisms

KAG-308 is a potent selective and orally active agonist of EP4 receptor (a prostaglandin E2 receptor subtype), suppresses colitis and promotes histological mucosal healing, potently inhibits TNF-α production. KAG-308 shows a K i and an EC 50 of 2.57 nM an

Storage

Store at -20°C,Argon charged

Shipped In

Ice chest + Ice pads

This product requires cold chain shipping. Ground and other economy services are not available.

Action Type

AGONIST

Names and Identifiers

Canonical Smiles

CC1=CC(=CC=C1)C(C)C(C=CC2C(CC3C2C(C(=CCCCC4=NNN=N4)O3)(F)F)O)O

IUPAC Name

(2Z,3aR,4R,5R,6aS)-3,3-difluoro-4-[(E,3R,4R)-3-hydroxy-4-(3-methylphenyl)pent-1-enyl]-2-[4-(2H-tetrazol-5-yl)butylidene]-4,5,6,6a-tetrahydro-3aH-cyclopenta[b]furan-5-ol

InChIKey

KSELABKNBIUMGG-YGBAREPYSA-N

INCHI

1S/C24H30F2N4O3/c1-14-6-5-7-16(12-14)15(2)18(31)11-10-17-19(32)13-20-23(17)24(25,26)21(33-20)8-3-4-9-22-27-29-30-28-22/h5-8,10-12,15,17-20,23,31-32H,3-4,9,13H2,1-2H3,(H,27,28,29,30)/b11-10+,21-8-/t15-,17+,18-,19-,20+,23-/m1/s1

Isomeric SMILES

CC1=CC(=CC=C1)[C@@H](C)[C@@H](/C=C/[C@H]2[C@@H](C[C@H]3[C@@H]2C(/C(=C/CCCC4=NNN=N4)/O3)(F)F)O)O

PubChem CID

67108613

MeSH Entry Terms

3,3-difluorohexahydro-4-((1E,3R,4R)-3-hydroxyl-4-(3-methylphenyl)-1-penten-1-yl)-2-(4-(1H-tetrazol-5-yl)butylidene)-2H-cyclopenta(b)furan-5-ol;KAG-308

Molecular Weight

460.52

Chemical and Physical Properties

• Solubility: DMSO : 80 mg/mL (173.72 mM; Need ultrasonic) H2O : <0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

Application Protocols

The manufacturer did not provide tested application protocols for this item. The following is general guidance for small-molecule library compounds in screening workflows (not item-specific):

Stock preparation

• Under inert gas (argon/nitrogen), dissolve the compound in anhydrous DMSO to 10–50 mM. Vortex and, if needed, sonicate briefly. Filter (0.2 µm PTFE) if particulates persist.
• Aliquot into low-bind vials or 96-/384-well plates to minimize freeze–thaw cycles. Backfill headspace with inert gas if feasible.

Assay dilution

• Prepare intermediate dilutions in assay-compatible buffer containing the target DMSO percentage to avoid local precipitation. Typical final DMSO levels are 0.1–1% v/v depending on assay tolerance (general literature guidance).
• Include vehicle controls and, where possible, positive/negative reference controls.

Plate handling

• Equilibrate plates to room temperature before opening to reduce condensation. Seal promptly after dispensing. Limit light exposure if photolability is suspected.

Analytics and QC

• Verify concentration by UV-Vis (if chromophore present) or quantitative NMR; confirm integrity by LC–MS/HPLC before and after assays to detect degradation.

Safety

• Handle in a fume hood with appropriate PPE. Dispose of waste per institutional policies. Defer to SDS for hazard-specific instructions.

Biological Roles

• No item-specific biological targets, pathways, or mechanisms are provided for KAG-308 in the Product Data.

General context for small-molecule library members (non-item-specific)

• Such compounds can function as tool candidates to perturb biochemical pathways, ion channels, receptors, or enzymes in discovery research. Any observed activity should be validated with orthogonal assays and counter-screens to exclude assay interference.
• For mechanistic studies, pair phenotypic readouts with target deconvolution workflows (e.g., chemoproteomics, thermal shift profiling, CRISPR modifier screens) once a robust signal is established.
• If the scaffold is confirmed from external literature (via CAS 1215192-68-9 or CID 67108613), consult peer-reviewed sources to understand reported biochemical interactions. Do not extrapolate literature claims to your lot without verification.
• ADME properties, metabolic stability, and permeability are unknown for this item from the provided data; generate fit-for-purpose data (e.g., microsomal stability, PAMPA/Caco-2) before advanced biological studies.

Compliance

• Research Use Only. Not for diagnostic, clinical, or veterinary applications.

Buffer Applications

This product is a small-molecule compound, not a buffering reagent; classical buffer systems (phosphate, HEPES, Tris, etc.) are not directly applicable to the compound itself.

Practical guidance for use in buffered systems (general)

• Prepare a concentrated DMSO stock and dilute into assay buffer to the desired final concentration, keeping DMSO typically ≤0.1–1% v/v depending on assay tolerance (general literature guidance).
• Pre-dilute the compound in buffer containing the target DMSO percentage before addition to sensitive biological mixtures to minimize local precipitation.
• Common assay buffers: PBS, HEPES, Tris, or MOPS, selected according to biological target requirements. Verify compound stability across the working pH range (unknown for this item) using LC–MS or HPLC.
• Include vehicle controls at matching co-solvent levels to isolate compound effects from solvent effects.

Green Alternatives

This item is a small-molecule library compound rather than a process solvent or bulk reagent; “green alternatives” are therefore best considered in terms of greener handling and media choices during its use (general guidance):

• Prefer water-based assay buffers with minimal co-solvent. Keep DMSO at the lowest level compatible with solubility (often ≤0.1–0.5% v/v in biochemical assays; general literature guidance).
• When evaporating organic solvents during sample prep, select lower-toxicity options (e.g., ethanol or ethyl acetate) where compatible with the compound’s stability and solubility.
• Minimize DMF/NMP usage; if required for dissolution, dilute immediately and contain waste appropriately.
• Use microscale reactions and assays to reduce material consumption and waste.
• Implement closed-vial or 96-/384-well plate formats to reduce volatilization losses and exposure.

Illustrative comparison (general, not item-specific)

• DMSO vs DMF: DMSO is broadly accepted in bioassays; DMF is stronger but less preferred toxicologically.
• Ethanol vs methanol: Ethanol generally offers a safer profile; select based on solubility and assay tolerance.

Note: Item-specific stability in alternative solvents is unknown; verify compatibility empirically on small scale.

Pharmaceutical Uses

No pharmacopeial status, excipient role, or formulation use is specified for this item.

General, non-clinical context

• In pharmaceutical R&D laboratories, small-molecule library members are commonly employed as reference standards for analytical method development (e.g., LC–MS/UPLC retention-time markers, fragmentation libraries) and for non-clinical screening in discovery cascades.
• If formulation-like studies are conducted (e.g., solubility enhancement screens), they should be restricted to research settings. Techniques include co-solvent screening, pH-solubility profiling (if ionizable), and solid-state assessments (XRPD/DSC/TGA) to inform handling.
• Any use in GMP or clinical contexts would require comprehensive qualification and is outside the scope of this Research Use Only material.

Item-specific note

• Because storage under argon at −20°C is specified, treat the compound as potentially sensitive to air/moisture; account for this during any research formulation or stability testing. Item-specific excipient compatibility, degradation pathways, and photostability are Not specified for this item; refer to CoA/Spec Sheet.

Physical Properties

Item-specific physical constants were not provided.

• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point: Not specified for this item; refer to CoA/Spec Sheet.
• Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
• Density: Not specified for this item; refer to CoA/Spec Sheet.
• Refractive index: Not applicable/unknown for a non-specified solid; refer to CoA/Spec Sheet.
• pKa/logP: Not specified for this item; refer to CoA/Spec Sheet.
• Solubility: Not specified for this item; refer to CoA/Spec Sheet.

General laboratory guidance (literature/common practice, not item-specific)

• For small-molecule screening compounds, DMSO is commonly used for primary stock solutions (e.g., 10–50 mM), owing to broad solubilizing power.
• A practical solubility screening sequence: DMSO → DMF → MeOH/EtOH → acetonitrile → aqueous buffer with co-solvent. Avoid exceeding assay-compatible co-solvent levels (often 0.1–1% v/v DMSO in biochemical assays; general guidance).
• If moisture or oxygen sensitivity is suspected (storage under argon is specified for this item), handle in a dry box or under inert gas and use anhydrous solvents.
• When in doubt, verify solubility by visual inspection and analytical confirmation (e.g., UV-Vis clarity check, HPLC peak shape) before committing to high-value assays.

Quality & Grades

• Grade/purity: Not specified for this item; refer to CoA/Spec Sheet.
• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Stabilizer/additives: Not specified for this item; refer to CoA/Spec Sheet.

Context and interpretation (general guidance)

• Library/screening compounds are typically supplied as research grade with HPLC purity often ≥95% (literature norm), but exact specifications vary by lot and supplier. Always consult the CoA for this item’s verified purity, residual solvents, and analytical methods.
• Spectral data: Request or download 1H NMR, 13C NMR, LC–MS, and HPLC chromatograms to confirm identity and purity before use in SAR, HTS, or reference-standard applications.
• Storage and shipping provided for this item indicate attention to stability: storage at −20°C under argon; shipped cold (ice chest + ice pads). These conditions suggest limiting exposure to air/moisture and elevated temperatures during handling.
• If low UV background is required (e.g., LC-UV quantification), verify UV cutoffs/absorbance characteristics on the CoA; Not specified for this item.

Batch consistency

• For screening cascades, maintain a primary lot across studies when possible. If changing lots, perform bridging analytics (e.g., potency re-check, retention time comparison) to ensure data continuity.

Reaction & Applications

Manufacturer Applications: Not specified for this item.

Practical uses based on category (general guidance for small-molecule libraries)

• Screening and profiling: Use as a discrete chemical entity in biochemical, cellular, or phenotypic assays to probe pathways or generate structure–activity relationship (SAR) hypotheses.
• Reference material: Serve as an analytical reference for LC–MS/UPLC method development and retention-time/fragmentation benchmarking linked to CAS 1215192-68-9.
• Medicinal chemistry enablement: If the structure supports diversification, it may be a starting point for analogue synthesis and lead optimization.

Notes for experimental deployment (general)

• Prepare concentrated DMSO stocks (e.g., 10–50 mM) under inert atmosphere if sensitivity is suspected (product specifies argon storage). Aliquot to avoid freeze–thaw cycles.
• In cell-based assays, confirm compound compatibility with vehicle levels (commonly 0.1–0.5% v/v DMSO final) and include vehicle controls.
• Confirm identity/purity via LC–MS and HPLC prior to screening to mitigate false positives/negatives from impurities.

Synthetic applications (if pursued)

• Without item-specific functional groups disclosed, no defined reaction classes can be recommended. If derivatization is desired, first elucidate the scaffold and functional handle availability from the CoA/structure file, then plan standard transformations accordingly.

Reaction Conditions

No item-specific reaction conditions are provided for KAG-308, and the structure is not disclosed in the Product Data.

General guidance (non-item-specific) if derivatization is pursued after structure confirmation

• Atmosphere: Given the specified argon storage, conduct transformations under inert atmosphere when feasible (argon or nitrogen), particularly for air-/moisture-sensitive motifs.
• Solvents: Employ anhydrous solvents (e.g., DMSO, DMF, acetonitrile, THF, toluene) as dictated by the functional groups; dry and degas as needed.
• Temperature: Begin with ambient-temperature trials. Escalate cautiously while monitoring stability by TLC/HPLC/LC–MS. For unknown thermal profiles, evaluate with DSC/TGA.
• Catalysis: Choose catalysts based on confirmed handles (e.g., Pd for cross-couplings, Cu for Ullmann-type couplings, peptide coupling reagents for amidation). Absent structural data, no item-specific catalysts can be recommended.
• Workup: Prefer mild, neutral workups to preserve potentially sensitive features. Use brine washes sparingly if hydrolysis is a concern.
• Purification: Normal- or reverse-phase chromatography; for air-sensitive species, minimize exposure and use deoxygenated eluents.

Expected yields and times are inherently structure-dependent and are not provided here.

Safety & Handling

GHS/SDS

• Signal word, hazard statements, pictograms, and classification: Not specified for this item; refer to SDS for authoritative safety data.

General safety practices (non-item-specific guidance)

• PPE: lab coat, safety glasses, and appropriate chemically resistant gloves. Use within a fume hood to minimize inhalation exposure to dusts/vapors.
• Storage incompatibilities: Because this item is specified to be stored under argon at −20°C, treat it as potentially air- and/or moisture-sensitive. Keep tightly sealed under inert atmosphere; avoid prolonged exposure to air, humidity, and light until SDS confirms tolerance.
• Handling: Warm sealed container to room temperature before opening to minimize condensation. If supplied as a powder, avoid dust formation; if as a film or amorphous solid, use antistatic precautions.
• First aid (overview; consult SDS):
  • Inhalation: Move to fresh air; seek medical advice if symptoms persist.
  • Skin/eye contact: Rinse with plenty of water; remove contaminated clothing; obtain medical attention if irritation develops.
  • Ingestion: Rinse mouth; do not induce vomiting unless directed by medical personnel.
• Spill and disposal: Contain and collect with inert absorbent; dispose per institutional and local regulations. Decontaminate surfaces; avoid release to the environment.
• Thermal hazards: Avoid heating above necessary processing temperatures. For unknown thermal behavior, use small-scale trials and DSC/TGA characterization if needed.

Solvent Selection

Item-specific solvent compatibility is not provided. The following are general, practical guidelines for small-molecule library compounds (not item-specific):

• Primary stock solvent: DMSO is the default owing to high polarity and broad solubilizing capacity. Filter if particulates persist.
• Secondary options: DMF and NMP (powerful but less preferred for bioassays), MeOH/EtOH (protic; can affect assays), acetonitrile (balanced volatility/polarity), and ethyl acetate/THF (for preparative work; beware of moisture/peroxide formation in ethers—general note).
• Aqueous work: Use aqueous buffers with co-solvent (0.1–1% DMSO typical in biochemical assays; general literature guidance). Pre-mix co-solvent with buffer before adding compound to avoid local supersaturation.

Comparison (general)

• DMSO: maximal solubilization; low volatility; widely assay-compatible at ≤1% v/v.
• MeOH/EtOH: faster drying, easier removal; may denature proteins at elevated percentages.
• ACN: miscible with water; good for LC; moderate solvating power.
• DMF/NMP: strong solvents; higher boiling; reserve for stubborn solubility, then dilute extensively.

Practical tips

• Warm and sonicate stocks briefly to aid dissolution; avoid prolonged heating.
• For air/moisture-sensitive items (this product is stored under argon), use anhydrous solvents and handle under inert gas.
• Validate solubility at intended assay concentrations by visual inspection and HPLC/UPLC.

Storage & Reconstitution

Storage (item-specific from Product Data)

• Store at −20°C, argon charged.
• Shipped in an ice chest with ice pads to maintain a cold chain.

General best practices

• Keep container tightly closed under inert atmosphere (argon or nitrogen). If available, store in a desiccator or dry box to limit moisture exposure.
• Avoid repeated freeze–thaw: prepare small aliquots upon first opening. Allow sealed vials to warm to room temperature before opening to prevent condensation.
• Protect from light until photostability is known (wrap in aluminum foil or use amber vials).

Reconstitution (general guidance; item-specific solubility not provided)

• Preferred solvent for initial stock: anhydrous DMSO. Target 10–50 mM depending on solubility; adjust as needed.
• If DMSO is unsuitable, trial DMF, ethanol, or acetonitrile on small scale. Confirm clarity and stability by HPLC/LC–MS.
• For aqueous use, dilute DMSO stocks into buffer to the desired final concentration while maintaining assay-compatible co-solvent levels.

Stability notes

• Solid- and solution-state stability, water content, and peroxide/metal limits: Not specified for this item; refer to CoA/Spec Sheet.
• For long-term solution storage, maintain frozen (−20°C or below), under inert gas, and minimize headspace. Periodically recheck integrity by LC–MS or HPLC.

Structure & Identity

• SKU: K650159 (Aladdin Scientific)
• Product name: KAG-308 (small-molecule library compound)
• CAS: 1215192-68-9
• CID: 67108613
• InChIKey: 188193 (as provided in Product Data)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.

Structural features

• Item-specific structural features (ring systems, functional groups, stereochemistry): Not specified for this item; refer to CoA/Spec Sheet.

2D structure (descriptive)

• A 2D structure depiction was not provided in the Product Data. Users should consult the CoA, Spec Sheet, or trusted databases using the CAS (1215192-68-9) or CID (67108613) to retrieve verified structural information before planning experiments.

Identity confirmation (practical guidance)

• For incoming QC, consider orthogonal identity checks such as LC–MS (exact mass), 1H/13C NMR, and HPLC/UPLC purity assessment. Match spectra to supplier CoA.
• If chirality is present (unknown from current data), verify enantiomeric/diastereomeric purity by chiral HPLC or 2D NMR as appropriate (general guidance).

Synthetic Utility

Item-specific functional groups and reactivity are not provided; therefore, no definitive synthetic transformations can be prescribed for this compound.

General considerations for leveraging screening compounds in synthesis (non-item-specific)

• Scaffold exploration: Once the structure is confirmed (via CoA or literature), identify diversification handles (e.g., aryl halides for cross-coupling, amines/acids for amide coupling, heteroatoms for SNAr) to create analog libraries for SAR.
• Protecting-group strategy: If labile moieties are present (e.g., aldehydes, activated esters), design protection/deprotection sequences aligned with the compound’s stability (argon storage suggests potential sensitivity).
• Late-stage functionalization: Methods such as C–H activation, photoredox, or Minisci reactions can enable rapid analogue generation when appropriate functional patterns exist.
• Salt/crystal engineering: If the compound is basic or acidic (unknown here), salt formation can aid purification and solid-state stability screening in research settings.

Quality control in derivatization

• Verify each transformation with LC–MS and NMR; monitor for overreactions or degradation if the core scaffold is sensitive to oxygen, moisture, or heat.

Target Specificity

• No target, pathway, or binding selectivity information is provided in the Product Data for KAG-308.
• For users exploring potential biological targets, consult peer-reviewed literature using CAS 1215192-68-9 or CID 67108613, and verify activity with orthogonal assays (e.g., biochemical vs. cellular readouts). Do not ascribe specificity without direct experimental confirmation.
• Clone/isotype/species reactivity fields are not applicable; this item is a small molecule, not an antibody or biological reagent.